Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

This creates tremendous value for our Vertex community. At a customer event in Germany in September, we previewed our ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one ...

William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating today. Jake Roberge has given his ...

Micron announced changes to its Board of Directors on Wednesday. Micron said Robert (Bob) Switz, its current Board Chair, ...

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 14 cents per share. The company posted revenue of $170.4 ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

Hello and thanks for joining us to discuss Vertex Inc third quarter financial results. I'm Joe Crivelli, Vice President, Investor Relations, David DiStefano, our President and CEO and John Schwab. Our ...